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CHAPTER  9
Summary and future perspectives




Medical treatment for patients with breast cancer has achieved considerable 
improvement over the past three decades. The adoption of breast conserving surgery in 
patients with early breast cancer preserves normal breast tissue as well as the cosmetic 
outcome without compromising radical tumor resection and consequently patients’ 
survival1. Subsequently, the replacement of axillary lymph node dissection by a sentinel 
lymph node biopsy in patients with clinically negative nodes reduces surgical side effects 
such as lymphedema and shoulder-arm function impairment, without increasing local 
recurrence and impairing patients’ survival2. Improvement of systemic therapy, such as 
the use of anthracyclines, taxanes, trastuzumab and aromatase inhibitors, has reduced 
recurrence risk and breast cancer related death3,4. Although this progress in treatments 
for breast cancer has been achieved, up to 30% of all patients with primary breast 
cancer will still develop local or distant recurrence4. This illustrates that there is a need 
for optimizing these multidisciplinary treatments. For adequate treatment decision-
making it is important to obtain information on the residual tumor in breast or axilla and 
characteristics of the tumor and its associated microenvironment. 
Novel imaging techniques such as micro-computed tomography (micro-CT) and 
fluorescent optical molecular imaging can potentially provide information intraoperatively 
about the surgical margin status in terms of a positive or negative margin. Mathematical 
models might support the clinical decision-making process by predicting preoperatively 
the probability of axillary lymph node metastasis, whereas detailed dissection of the 
tumor immune microenvironment may support better understanding of the tumor 
biology and further better systemic treatment combination. 
The aim of this thesis is to evaluate novel minimal invasive approaches in supporting 
de-escalation of surgical treatment and optimization of systemic treatment for breast 
cancer.
In Chapter 1, a short introduction and outline of the thesis is provided. 
In Chapter 2 to Chapter 6, the de-escalation in the surgical treatment of breast cancer 
is described. In Chapter 2, we have reviewed the evolution of sentinel lymph node 
biopsy (SLNB) in breast cancer. We searched literature and ongoing clinical trials related 
to SLNB in breast cancer until December 2016. In early breast cancer patients with 
clinically negative axillary lymph nodes and pathologically negative sentinel nodes, 
SLNB substantially reduces surgical complications while achieving comparable local 
recurrence and survival rates compared with axillary lymph node dissection (ALND). 
Similar results have been observed for patients with micrometastatic sentinel nodes or 
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patients with T1-2 tumor, 1-2 positive sentinel nodes and receiving breast conserving 
surgery combined with whole-breast radiation therapy. SLNB after neoadjuvant systemic 
therapy in patients with pretreatment positive axillary lymph nodes is considered feasible 
in the following circumstances: i) three or more sentinel nodes had been removed, ii) 
pretreatment-positive nodes had been marked and removed combined with SLNB, and 
iii) immunohistochemistry had been used for sentinel node examination. Currently used 
agents for sentinel node mapping have their own drawbacks, such as allergic reactions 
from blue dyes or unavailability of 99Tc-radiocolloid in many developing countries. To 
avoid these drawbacks, some new non-radioactive methods, such as indocyanine 
green or superparamagnetic iron oxide, have been developed for the detection of the 
sentinel nodes and showed non-inferiority to the conventional methods. These methods 
may be alternatives to 99Tc-radiocolloid in those countries that have less easy access 
to radioactive compounds. To avoid the complications of axillary lymph node surgery, 
omission of the procedure in patients with low risk of axillary lymph node metastasis is 
currently investigated by several clinical trials, such as the Sentinel Node Vs Observation 
after Axillary Ultra-souND trial (SOUND, NCT02167490).
In Chapter 3, a predictive model is described that was developed to predict the risk of 
axillary lymph node metastasis in patients with operable breast cancer and one or more 
axillary lymph nodes detected by a preoperative ultrasound. A consecutive set of 556 
Chinese patients diagnosed at the Cancer Hospital of Shantou University Medical College 
were included. Data of the first 322 patients was used to develop the model, and data of 
the other 234 patients was used to validate the model. Multivariable logistic regression 
analysis identified six independent predictors which were incorporated in the predictive 
model. These were clinical tumor size, estrogen receptor (ER) status, histological grade 
of the primary tumor, and transverse diameter, cortical thickness and hilum status of 
the axillary lymph node as detected by preoperative ultrasound. The discriminative 
performance of the model was evaluated by the area under the receiver operating 
characteristic curve (AUC). The model showed good performance in axillary lymph node 
metastasis prediction with an AUC of 0.864 in the 234 patients validation set. In order 
to test the generalizability of the model in patients of different ethnic origin, in Chapter 
4 we performed an external validation of the model using data of 1,416 Dutch patients 
from six hospitals. The clinicopathological data of patients was retrospectively collected 
from the database of the Netherlands Cancer Registry combined with ultrasound reports 
and images in each participating hospital. In general, the model performed well in Dutch 
patients with an AUC of 0.774. However, it underestimated the risk of axillary lymph node 
metastasis in low-risk patients; a similar underestimation was observed in the Chinese 
validation set. Therefore, we updated the model using the generalized linear model tree 
analysis to improve its predictive accuracy, especially for the patients with low risk of 
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axillary lymph node metastasis. In the Dutch validation set, the updated models showed 
more accurate prediction in axillary lymph node metastasis compared with the original 
model, especially for the low-risk patients. Moreover, the discriminative performance 
of the updated models remained well (AUC = 0.851) in the Chinese patients, indicating 
generalizability of the updated models. Using the updated models, we were able to 
identify a subset of patients with low risk of axillary lymph node metastasis, who could 
be candidates for axillary surgery omission.
In Chapter 5, we investigated the feasibility and accuracy of micro-CT imaging of surgical 
specimen for surgical margin assessment in breast conserving surgery. Thirty surgical 
specimens from 30 patients with early breast cancer who underwent breast conserving 
surgery were included for micro-CT scanning. The whole surgical specimen was scanned 
intraoperatively after lumpectomy. Image reconstruction was performed immediately 
after specimen scanning. Micro-CT images were analyzed retrospectively to evaluate the 
surgical margin status, which was compared to the final histopathological margin status. 
The time needed for tissue scanning, image reconstruction and image evaluation were 
7-, 1.5- and 5 minutes, respectively. This suggests that micro-CT is technically feasible 
for intraoperative back-table use as it enables quick feedback to surgeons on the margin 
status. The tumor in one patient was not visualized in micro-CT images because of the 
dense surrounding breast tissue, resulting in 29 patients with margin status analyzable 
in micro-CT images. In these 29 patients, nine tumors had histopathologically positive 
and 20 had negative margins. Micro-CT correctly predicted the positive surgical margin 
status in five out of nine patients, and negative margin status in all of the 20 patients. 
This generated a 56% sensitivity and 100% specificity in margin status prediction. The 
reoperation rate could potentially have been reduced from 31% to 14% if micro-CT was 
intraoperatively used back-table to guide surgical decision-making. Therefore, further 
studies with larger cohorts of patients are warranted to determine the added value of 
intraoperative use of micro-CT for the standard surgical procedure regarding reduction 
of reoperation rates.
In Chapter 6, we describe a dose-escalation phase II trial investigating the optimal dose 
of bevacizumab-800CW for fluorescent image-guided surgery in breast conserving 
operations. Twenty-six patients with primary breast cancer received a bolus intravenous 
injection of 4.5 mg (three patients), 10 mg (10 patients), 25 mg (10 patients) and 50 
mg (three patients) of the near-infrared fluorescent tracer bevacizumab-800CW 3 days 
before surgery. Fluorescent intensities of the breast cancer tissue and surrounding normal 
tissue were measured at the macroscopic level in freshly sliced tissue. Tracer tumor-
specific targeting in a dose-dependent manner was observed. This resulted in increased 
signal to background ratios, which reached a plateau at 25 mg. At the microscopic level in 
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10-μm-thick tissue slides, the biodistribution of bevacizumab-800CW within the tumor 
was assessed by measuring the fluorescent intensity of different tissue components in 
the tumor. All tumor tissue, irrespective of dosing, showed a higher mean fluorescence 
intensity compared to the surrounding normal breast tissues. The intraoperative 
fluorescence images and videos of the surgical cavity of all patients were analyzed 
retrospectively to evaluate the surgical margin status. Bevacizumab-800CW fluorescent 
image-guided surgery improved the detection of tumor-involved margin in 88% of the 
patients with a positive surgical margin, indicating its potential clinical impact. Due to 
the unequal distribution of patients with a positive margin in the four dose groups and 
possibly the presence of tumor heterogeneity, the optimal tracer dose for fluorescent 
image-guided surgery could not be concluded. Based on data acquired in this phase II 
dose-escalation trial, we developed an analytical framework for standardization in data 
collection and fluorescence image analyses. This analytical framework can be used as 
a road map for the clinical translation and evaluation of tumor-targeted fluorescent 
tracers for molecular fluorescence-guided imaging and it may be applicable for a wider 
range of tumor types and different classes of optical tracers.
From Chapter 7 to Chapter 8, detailed dissection of tumor immune microenvironment 
in breast cancer is described. In Chapter 7, we have reviewed the rationale for targeting 
tumor-associated macrophages (TAMs) in breast cancer. A literature search was performed 
to acquire data on the prognostic value of TAMs in breast cancer patients, preclinical 
evidence on the role of TAMs on breast cancer cell growth, metastasis and treatment 
resistance, and clinical studies on macrophage-targeted therapies until June 2018. In 
general, a higher infiltration of TAMs in the primary tumor is associated with unfavorable 
clinicopathological features and worse prognosis in patients with early breast cancer, 
although conflicting results do exist in literature. The subtype and localization of TAMs 
are important when evaluating their prognostic value in breast cancer. Moreover, the 
prognostic value of TAMs may be breast cancer subtype dependent. Preclinical studies 
showed that TAMs promote breast cancer cell growth, local invasion, intravasation, 
extravasation and metastatic tumor growth. Furthermore, TAMs induce resistance to 
multiple types of treatment in breast cancer mouse models. The underlying mechanisms 
include: induction and maintenance of tumor-promoting phenotype in TAMs, inhibition of 
CD8+ T cell function, degradation of extracellular matrix, stimulation of angiogenesis and 
inhibition of phagocytosis. Inhibition of macrophage recruitment, repolarization of TAMs 
to an antitumor phenotype, and enhancement of macrophage-mediated phagocytosis 
inverse the treatment resistance mediated by TAMs in preclinical mouse models. Based 
on these data, macrophage-targeted treatment strategies have been developed and are 
currently being evaluated in early phase clinical breast cancer trials. However, the clinical 
efficacy of targeting TAMs in breast cancer remains to be established.
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In Chapter 8, we analyzed the androgen receptor expression (AR) and immune 
microenvironment of the primary tumors from 221 patients with human epidermal 
growth factor receptor 2 (HER2)-positive metastatic breast cancer. These patients 
treated with trastuzumab when they developed metastatic disease were identified 
from 19 hospital pharmacies in the Northern part of the Netherlands. Sufficient primary 
tumor material was available for analysis in 150 patients. AR and the immune marker 
expression were evaluated by immunohistochemistry or immunofluorescence staining. 
AR was expressed in 81.3% of the tumors and was inversely correlated with infiltration 
of M2 TAMs, CD3+ and CD8+ T cells. Clustering analysis was performed to dissect the 
AR expression and immune cell composition in individual tumors, which were classified 
into four subgroups. These subgroups were: i) tumors with high immune cell infiltration 
and low AR expression (around 20%), ii) tumors with high immune cell infiltration and 
high AR expression (around 15%), iii) tumors with low immune cell infiltration and high 
AR expression (around 50%) and iv) tumors with low immune cell infiltration and low AR 
expression (around 15%). In tumors with high immune cell infiltration, high AR expression 
compared to low AR expression was associated with improved overall survival (89.7 vs 
66.4 months, P=0.01). Although this difference was found in a relatively small patient 
group, it may indicate that the proposed classification is relevant to clinical outcome. 
Therefore, future studies are warranted to validate our results.
Future perspectives
De-escalation in the surgical treatment of breast cancer
The trend of de-escalation in the surgical treatment of breast cancer is a new 
development in clinical practice which seems irreversible. The rate of breast conserving 
surgery has increased significantly over time, accompanied with a decrease in the rate 
of mastectomy5. The indication of SLNB has expanded from previously being executed 
in patients with clinically negative nodes to selected patients with clinically positive 
nodes who receive neoadjuvant chemotherapy. One could envision in the short coming 
future, especially when combined with radiotherapy, that complete omission of axillary 
surgery may be possible in a selected group of patients with breast cancer. However, 
several issues need to be addressed to further support surgical de-escalation in breast 
cancer. First, there will be a need for the improvement of the acceptance of more limited 
surgical approaches among breast cancer surgeons. The ACOSOG Z00116, AMAROS7, and 
IBCSG 23-018 randomized trials demonstrated that ALND is not necessary for all patients 
with sentinel node metastases. However, there were still approximately half of the 
breast cancer surgeons recommend to perform ALND for patients meeting the Z0011 
trial inclusion criteria, as demonstrated in a recently published survey including 376 
surgeons9. In 2014, the Society of Surgical Oncology and American Society for Radiation 
Oncology published the “no ink on tumor” consensus guideline as the definition of a 
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negative margin based on a systematic review of 33 studies including 28,162 patients. 
Wider margin widths do not lower ipsilateral breast cancer recurrence compared to 
the “no ink on tumor” definition1. After publication of this guideline, only around two 
third of the 342 surgeons who participated in a recently published survey endorsed the 
“no ink on tumor” definition. Nevertheless, the increased acceptance of this guideline 
consensus contributed to an absolute 16% decrease of reoperation rate after the primary 
lumpectomy5. Surgeons with less acceptance of the “no ink on tumor” consensus 
guideline as an adequate surgical margin, were also less likely to accept a more limited 
axillary surgery9. A higher number of breast cancer cases seen annually was associated 
with higher acceptance of the “no ink on tumor” guideline and ALND omission5,9. This 
data indicates quite some room for improvement in the acceptance of more limited 
surgery by surgeons and suggests a need for ongoing education of surgeons, especially 
for those with a lower annual patient volume.
The second factor of importance for surgical de-escalation is the need to validate the 
results of novel techniques from early studies in a standardized way among hospitals. This 
can facilitate the translation of these results to standard care. The two studies presented 
in this thesis were a feasibility study (Chapter 5 micro-CT) and an early phase clinical trial 
(Chapter 6 fluorescent optical molecular imaging) which obtained information about 
the value of two novel techniques to assess intraoperatively the margin status in breast 
conserving surgery. These techniques need further evaluation in larger multicenter 
clinical studies before they can be implemented into clinical practice. Currently, the 
accuracy of micro-CT technique for intraoperative surgical margin assessment is 
investigated in two larger studies executed in the Netherlands Cancer Institute (250 
specimens) and the Massachusetts General Hospital (107 specimens), respectively. In 
these studies, new methods for image reconstruction are also explored to reduce the 
reconstruction time and improve the image quality and thus interpretation of data. A 
standardized analytical method for micro-CT technique including tissue handling and 
scanning, image reconstruction and image analysis needs to be established in these 
studies. This will facilitate a future multicenter prospective interventional study assessing 
the value of micro-CT technique in reduction of reoperations after lumpectomy. The 
clinical impact of bevacizumab-800CW on reduction of the number of positive margin 
rates and reoperations after lumpectomy will be assessed in an upcoming phase III 
multicenter clinical trial. To maximize the opportunity for clinical translation, it is crucial 
to make sure that the results obtained from multiple centers are comparable. To achieve 
this, standardized data collection and fluorescence image analyses is the key. Therefore, 
the standardized analytical framework developed in Chapter 6 will serve as a novel tool 
in multicentre studies. 
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The third factor, will be a need to take the breast cancer biology into account to optimize 
the surgical de-escalation in breast cancer. For example, the overall nodal pathologic 
complete response (pCR) with neoadjuvant chemotherapy ranges from 40% to 60% 
overall, and increases to 70% to 80% among patients with HER2-positive and triple-
negative tumors10. In a retrospective study of 1,907 patients with cN0 breast cancer, a 
multivariable analysis found that in patients with HER2-positive or triple-negative tumors 
treated with mastectomy, neoadjuvant chemotherapy reduced the need for ALND. 
However, this effect was not observed in hormone receptor-positive/HER2-negative 
tumors11. This indicates that patients with HER2-positive or triple-negative tumors may 
have a higher chance to allow avoiding ALND following neoadjuvant chemotherapy, 
which warrants further investigation. In patients receiving a breast conversing surgery, 
nowadays it is clear that tumor biology is associated with local recurrence rate, which 
varies with hormone receptor and HER2 status. Patients with triple negative breast 
cancer have the highest local recurrence rate and patients with hormone receptor-
positive/HER2-negative breast cancer have the lowest local recurrence rate, regardless 
of whether treated with breast conserving surgery or mastectomy12. This indicates that a 
wider negative margin is not necessary in this subset of patients with a high risk of local 
recurrence.
When the above-mentioned issues are addressed, the surgical treatment for breast 
cancer will become more refined and therefore will result in less side effects and possibly 
in reduction of medical costs.
Dissection of tumor immune microenvironment in breast cancer
The breast cancer immune microenvironment comprises different types of immune 
cells, such as T-cell subsets, B-cell subsets, plasma cells, nature killer cells and myeloid 
subsets. These cells demonstrate different prognostic and predictive values in patients 
with breast cancer13. Moreover, these cells may interact with each other, as well as 
with breast cancer cells and other cells in the microenvironment such as fibroblast. It 
is important in future studies to reveal these interactions to get better understanding 
of breast cancer biology and further support more personalized and optimized systemic 
treatment combination.
Monitoring the heterogeneity (among patients and between primary and metastatic 
tumors) and dynamics of immune cell compositions within tumors is another important 
aspect to support more personalized and optimized treatment decision-making. 
Techniques such as targeted molecular PET imaging, which can provide whole body 
imaging, might be used for non-invasively in vivo monitoring immune cells. However, 
it will be a challenge to simultaneously image different immune cell compositions in in 
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vivo setting. Biopsies combining with multicolor fluorescent staining might be able to 
demonstrate a more complete picture of immune cell compositions in a tumor. However, 
multiple biopsies in metastatic lesions and during the treatment are invasive and patient-
unfriendly and thus impractical. A combination of tissue ex vivo multicolour fluorescent 
staining and targeted molecular whole-body imaging may open a new window for better 
monitoring of the heterogeneity and dynamics of immune cell compositions, a concept 
warrants further study.
The various breast cancer molecular subtypes differ in their immunogenicity. Certain 
subtypes, in particular ER-negative and ER-positive/HER2-positive tumors show evidence 
of a relevant interaction between tumor and immune cells14. It might be worth in future 
studies to dissect the immune compositions, as well as their prognostic and predictive 
values, in these subtypes to consider systemic treatment strategy based on tumor-
immune biology.
In summary, to optimize the multidisciplinary treatment of breast cancer, continuing 
education for breast surgeons in combination with considering of tumor biology 
may support refinement of surgical de-escalation, whereas better learning of the 
heterogeneity, dynamics and interactions of immune compositions in breast cancer, 
especially in different molecular subtypes, might improve systemic treatment 
combination.
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